Aurobindo Pharma arm AP facility gets EIR from USFDA
Hyderabad: Aurobindo Pharma has announced that the new injectable facility of Eugia Steriles Private Limited (a 100 percent subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of the Company), situated at Parawada Mandal, Anakapalli District, Andhra Pradesh has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA).
The USFDA had conducted a Pre-Approval Inspection (PAI) of the said injectable facility from March 28, 2024 to April 05, 2024.
"The Unit has now received the Establishment Inspection Report (EIR) and the inspection is closed," the Company stated in a BSE filing.
Read also: Aurobindo Pharma step-down arm AP facility gets product approval from USFDA
Medical Dialogues team had earlier reported that the inspection of the said facility had closed with 3 observations.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.